Covance Partners with RBM to Extend Biomarker Offering

According to this article in outsourcing-pharma.com Covance will outsource biomarker activities to Rules Based Medicine, which is a US based laboratory group. Demand for biomarker services and the use of biomarker analysis in clinical trials has increased dramatically, and so this couldn't come at a better time.

Before the deal took place Covance had also begun building biomarker capacity. Under the deal RBM will apply its multi-analyte profile (MAP) technologies to projects being carried out by Covance's customers.

Forced Degradation Brochure Now Available

IIR’s Forced Degradation Forum is returning and updated with ALL NEW information and updates on the latest forced degradation insights and advances. Over the last six years, IIR’s Forced Degradation conferences have become catalysts for scientific progress and improvements in forced degradation testing and analysis. Join IIR and event co-founders Karen Alsante (Pfizer) and Steve Baertschi (Eli Lilly), for another ground-breaking event that addresses the latest challenges at the 6th annual Forced Degradation Forum.

Brochure Now Available for Download!

Explore What’s New NOW in Forced Degradation
→ Dive deeper into practical solutions & experimental tools for oxidation, photostability, and chemical reactions
→ Generate valuable insight into the potential for forming genotoxic degradants to support proactive strategies to control them
→ Uncover the latest advances in software to predict forced degradation to enrich the interpretation of experimental results.
→ Expand the effectiveness of individual scientists through the use of new software resources
→ Tap into the newest concepts in stress testing to improve performance and efficiency
→ Discover new tools to conduct automated FD in early & late phases

We look forward to seeing you in Philadelphia!

P.S. Register before January 8th and Save $400 when you mention code 0IY73U

Call for Bloggers: Attend Partnerships in Clinical Trials Asia Pacific on Us!

That’s right, we’re offering a few exclusive all-access complimentary passes to Partnerships in Clinical Trials Asia Pacific – December 1-3 in Singapore, and you could attend the conference – on us ($3,000+ value). We’re looking for experienced bloggers who are well-versed in clinical trials management to begin blogging now and also at this year’s event. In return for your posts, you’ll be able to attend educational sessions and training seminars delivered by industry thought-leaders and Pharma professionals through in-depth case studies featuring the industry experts from leading pharmaceutical companies and CROs and more. Network and engage with speakers from Bristol-Myers Squibb, Wockhardt, Biogen Idec, PPD, Allergan, CK Life Sciences, and more.

To apply to be a guest blogger, simply send your name, title, company and a few writing samples (a link to your blog is recommended) to Jennifer Pereira at jpereira@iirusa.com no later than Monday, November 23. We will review the submissions and contact all winners directly with more details. This opportunity doesn’t come often and we encourage you to apply and join us next month in Singapore.

For more information about the event, please follow the links below:

For more on the Partnerships in Clinical Trials Asia Pacific event, visit the website:
http://bit.ly/3snoyU

Download the Brochure: http://bit.ly/ZmGid

Partnerships in Clinical Trials Blog: http://bit.ly/1daSdF

Forced Degradation Forum Brochure Available

IIR’s Forced Degradation Forum is returning and updated with ALL NEW information and updates on the latest forced degradation insights and advances. Over the last six years, IIR’s Forced Degradation conferences have become catalysts for scientific progress and improvements in forced degradation testing and analysis. Join IIR and event co-founders Karen Alsante (Pfizer) and Steve Baertschi (Eli Lilly), for another ground-breaking event that addresses the latest challenges at the 6th annual Forced Degradation Forum.

Explore What’s New NOW in Forced Degradation
→ Dive deeper into practical solutions & experimental tools for oxidation, photostability, and chemical reactions
→ Generate valuable insight into the potential for forming genotoxic degradants to support proactive strategies to control them
→ Uncover the latest advances in software to predict forced degradation to enrich the interpretation of experimental results.
→ Expand the effectiveness of individual scientists through the use of new software resources
→ Tap into the newest concepts in stress testing to improve performance and efficiency
→ Discover new tools to conduct automated FD in early & late phases

We look forward to seeing you in Philadelphia!

Register before January 8th and Save $400 when you mention code 0IY73U

Forced Degradation Forum

Contract Research Remains Strong According to F&S Analyst

I came across this podcast on the Outsourcing-pharma blog in which Barath Shankar an industry analyst with Frost & Sullivan offers his opinion on the state of the sector since M&A activity is dominating Big Pharma's agenda at the moment, and to predict how it will develop.

Listen to the 5 minute podcast

A new way to find potential clinical trial participants

Nashville Public Radio reports on a new system developed by Vanderbilt University that will help individuals find clinical trials. The new software will allow individuals to search for clinical trails taking place. Researchmatch.org allows individuals to enter their demographic information, health conditions, and how far they’re willing to travel for a study, then those conducting clinical trials can search the database. Do you think this is a significant breakthrough for scientists? Do you see the numbers of participants in certain clinical trials increasing?

Partnerships In Clinical Trials Expands Its Global Reach

The Institute for International Research is pleased to announce that as a chief component of its global branding strategy, the industry-leading Partnerships with CROs event is now known as Partnerships in Clinical Trials. In the nineteen years since the inception of the event, both the biopharmaceutical industry and Partnerships have experienced tremendous growth as outsourcing to suppliers has become more than simply a tactic to control costs, but a leading strategic directive to ensure speed, quality and value of new medicines. “The name Partnerships in Clinical Trials reflects the comprehensive nature of the program, which is the must-attend annual event for clinical outsourcing and development professionals and is increasingly valuable to those with responsibilities in clinical operations, clinical project management, drug safety and quality,” said program director Lesly Atlas. “Our new name also represents our widening global reach with Partnerships in Clinical Trials events already taking place in Europe and the premier of our APAC event in Singapore this December. Collectively the Partnerships in Clinical Trials brand serves over 35 countries.”

Notable speakers include:

• Tom Daschle, Former Senate Majority and Minority Leader, US Senate
• David Holveck, President and CEO, Endo Pharmaceuticals
• Nancy Simonian, MD, Chief Medical Officer and Senior Vice President of Clinical, Medical, and Regulatory Affairs, Millennium: The Takeda Oncology Company
• Ethan Zohn, Winner of Survivor: Africa Chris Anderson, Editor-in-Chief, Wired Magazine and NYT Bestselling Author, The Long Tail: Why the Future of Business is Selling Less of More
• Thomas Senderovitz, MD, Vice President, Global Exploratory Development, UCB Pharma - Belgium
• Jason Hwang, MD, Executive Director, Innosight Institute
• Deirdre BeVard, Vice President, Clinical Operations and Data Management, Endo Pharmaceuticals
• Reinilde Heyrman, Vice President, Clinical Development and Operations, Daiichi Sankyo Pharma Development
• Peter Carberry, Senior Vice President, Global Development Operations, Astellas Pharmaceuticals
• Kenneth Getz, Senior Research Fellow, Tufts Center for the Study of Drug Development
• John Balian, MD, Senior Vice President, Global Pharmacovigilance and Epidemiology, BRISTOL-MYERS SQUIBB
• Amrit Ray, MD, MBA, FCMI, Chief Safety Officer, Head, Global Medical Safety, JOHNSON & JOHNSON PHARMACEUTICALS GROUP
• Philippe Van der Auwera, MD, PhD, Global Head of Safety Risk Management (PDS) & EU-QPPV, Pharma Development, F.HOFFMANN-LA ROCHE LTD - Switzerland
• Mariette Boerstoel-Streefland, MD, MBA, MS(epi), Chief Safety Officer, Vice President, Global Drug Safety, FOREST RESEARCH INSTITUTE
• Juergen Schmider MD, PhD, Corporate Safety Officer and Vice President Global Pharmacovigilance & Epidemiology, CEPHALON, INC
• And many more – complete program information will soon be available at www.clinicaltrialpartnerships.com.

About Partnerships in Clinical Trials – Partnerships is the leading drug development event bringing clinical trials executives timely information and trends in sourcing models and successfully maintaining critical sponsor/provider relationships, as well as valuable best practices and networking for entire clinical teams. As the number one meeting place for clinical trial partners to gather under one roof, Partnerships in Clinical Trials is known for strategic program content that drives business forward and for unparalleled networking. Visit www.clinicaltrialpartnerships.com for more information.

To inquire about speaking, sponsoring or attending Partnerships in Clinical Trials, please contact Allison Rigels via email at ARigels@iirusa.com or phone at 646-895-7327.

Malaria vaccine trail to begin in east Africa

According to The East African, a Phase III trial has begun for a Malaria vaccine. Malaria is one of the most deadly diseases in the world, and scientists believe that it may only be eradicated by a vaccine. This will be tested in seven African countries, and it was the first vaccine developed for primary use in Africa. The research for this vaccine began in the late 1980s. Read the full article here.

Florida Senator wants to see clinical trial expenses covered by insurance

The Insurance Journal reports that Florida Senator Don Gaetz wants to to see insurance companies begin to cover the cost of clinical trials for cancer patients. If insurance companies do not begin to comply with his demands, he'll introduce a bill into the Florida legislature to begin to force them to do so. He feels that the patients who enter clinical trials should not have to do so at their own financial risk. Read the full article here.